Evidence map›Paper›PMID 29670356›Full record

ArticleNeuropsychiatric disease and treatment2018

Comparative effectiveness of switching paroxetine formulation for treatment of major depressive disorder: an open-label multicenter study.

Tempei Otsubo, Yoshinori Watanabe, Seiji Hongo, Mikichika Inoue, Kimiko Akimoto, Ken Murakami, Ryutaro Takahashi, Toshiaki Kikuchi

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychiatric disease and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Tempei OtsuboDepartment of Psychiatry, Tokyo Women's Medical University Medical Center East, Tokyo, Japan.
Yoshinori WatanabeHimorogi Psychiatric Institute, Tokyo, Japan.
Seiji HongoNanko Clinic of Psychiatry, Shirakawa, Japan.
Mikichika InoueIkebukuro Internal Medicine, Tokyo, Japan.
Kimiko AkimotoIkebukuro Internal Medicine, Tokyo, Japan.
Ken MurakamiMurakami Hospital, Tokyo, Japan.
Ryutaro TakahashiTakahashi Clinic, Tokyo, Japan.
Toshiaki KikuchiDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Keio University · JPTokyo Institute of Psychiatry · JPTokyo Women's Medical University Adachi Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo assess the effectiveness and safety of switching the antidepressant formulation from immediate-release (IR) to controlled-release (CR) paroxetine in patients with major depressive disorder (MDD). PATIENTS AND

methodsA total of 113 outpatients with MDD diagnosed according to the

resultsThe overall patient HSDS/HSAS scores significantly improved after switching from IR to CR paroxetine (

conclusionThese results suggest that switching the treatment from IR to CR paroxetine could improve depressive symptoms and decrease ADRs. However, these results may have been caused by the psychological effect of drug switching. Hence, future studies with blinded evaluation methods are required to confirm and expand our findings.

Indexed as

antidepressantcontrolled-release paroxetinedepressiondrug formulationimmediate-release

Identifiers

PMID29670356
PMCPMC5896672
OpenAlexW2795480616

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.